The estimated Net Worth of Peter Wirth is at least $953 Tausend dollars as of 8 December 2021. Mr. Wirth owns over 4,000 units of Syros Pharmaceuticals stock worth over $551,992 and over the last 8 years he sold SYRS stock worth over $277,568. In addition, he makes $123,476 as Independent Chairman of the Board at Syros Pharmaceuticals.
Sign up
Mr. Wirth SYRS stock SEC Form 4 insiders trading
Peter has made over 3 trades of the Syros Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,852 units of SYRS stock worth $277,568 on 8 December 2022.
The largest trade he's ever made was selling 78,454 units of Syros Pharmaceuticals stock on 23 June 2020 worth over $126,311. On average, Peter trades about 4,515 units every 45 days since 2017. As of 8 December 2021 he still owns at least 342,852 units of Syros Pharmaceuticals stock.
You can see the complete history of Mr. Wirth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Wirth biography
Peter Wirth J.D. serves as Independent Chairman of the Board of the Company. Mr. Wirth currently serves as chair of FORMA Therapeutics, Inc., a privately held small molecule drug discovery company, and as a senior advisor to Zai Lab Limited, a publicly traded biopharmaceutical company based in Shanghai, China. Mr. Wirth was a senior executive at Genzyme Corporation from 1996 until after its acquisition by Sanofi-Aventis in 2011, most recently serving as executive vice president, legal and corporate development, chief risk officer and corporate secretary. During his time at Genzyme, Mr. Wirth had senior management responsibility for the company’s legal function, corporate development function, molecular oncology division, polymer drug discovery and development division and enterprise risk management function. Mr. Wirth previously served as a director of Synageva BioPharma Corp., a biopharmaceutical company. Mr. Wirth received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.
What is the salary of Peter Wirth?
As the Independent Chairman of the Board of Syros Pharmaceuticals, the total compensation of Peter Wirth at Syros Pharmaceuticals is $123,476. There are 12 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
How old is Peter Wirth?
Peter Wirth is 69, he's been the Independent Chairman of the Board of Syros Pharmaceuticals since 2017. There are 1 older and 18 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
What's Peter Wirth's mailing address?
Peter's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Insiders trading at Syros Pharmaceuticals
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju und Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
What does Syros Pharmaceuticals do?
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
What does Syros Pharmaceuticals's logo look like?
Complete history of Mr. Wirth stock trades at Syros Pharmaceuticals, Zai Lab und Forma Therapeutics
Syros Pharmaceuticals executives and stock owners
Syros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Nancy Simonian,
President, Chief Executive Officer, Director -
Joseph Ferra,
Chief Financial Officer -
Jeremy Springhorn,
Chief Business Officer -
David Roth,
Chief Medical Officer -
Eric Olson,
Chief Scientific Officer -
Gerald Quirk,
Chief Legal & Administrative Officer -
Dr. Nancy A. Simonian M.D.,
Pres, CEO & Director -
Dr. David A. Roth,
Chief Medical Officer -
Dr. Eric R. Olson,
Chief Scientific Officer -
Richard Young,
Director -
Dr. Richard A. Young Ph.D.,
Scientific Founder, Member of Scientific Advisory Board & Director -
Mark Alles,
Independent Director -
Peter Wirth,
Independent Chairman of the Board -
Marsha Fanucci,
Independent Director -
Amir Nashat,
Independent Director -
Phillip Sharp,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
S. Gail Eckhardt,
Director -
Dr. Christian C. Fritz Ph.D.,
Head of Biology -
Naomi Aoki,
VP of Corp. Communications & Investor Relations -
Gerald E. Quirk,
Chief Operations Officer & Sec. -
Jason Haas,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dr. James E. Bradner M.D.,
Founder -
Alice Tsang Shaw,
Director -
Ventures Fund Iv, L.P.Flags...,
-
Sanj K Patel,
Director -
Vicki L Sato,
Director -
Michael W Bonney,
Director -
Colleen Elizabeth De Simone,
Principal Accounting Officer -
Robert Nelsen,
Director -
Venture Fund Vii, L.P.Arch ...,
-
Kyle D. Kuvalanka,
Chief Operating Officer -
Stephane Bancel,
Director -
Management Co. Vii, L.L.C.P...,
-
Pharm Tech Healthcare Fund ...,
10% owner -
Group, Llc Green Jeremy Red...,
-
Venture Fund Vii Lparch Ven...,
-
Healthcare Ventures Ii, L.P...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Kristin Stephens,
Chief Development Officer -
Deborah Dunsire,
-
Jason Haas,
Chief Financial Officer -
Timothy Tyson,
-
Conley Chee,
President & CEO -
Andrew M. Oh,